Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (CYYNF)
OTHER OTC:CYYNF
RESEARCH TOOLSreports
Cynata Therapeutics Limited (CYYNF) Stock Price & Analysis
3 Followers
CYYNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.07 - $0.24
Previous Close$0.19
Volume200.00
Average Volume (3M)200.00
Market Cap
$31.17M
Enterprise Value$15.26M
Total Cash (Recent Filing)AU$23.80M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 22, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding179,631,786
10 Day Avg. Volume20
30 Day Avg. Volume200
Standard Deviation0.21
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cynata Therapeutics Limited News
PremiumCompany Announcements
Cynata Spotlights Cymerus Platform at Biotech Summit
PremiumCompany Announcements
Cynata Therapeutics Plans New Share Issue
PremiumCompany Announcements
Cynata Therapeutics Acquires Innovative Wound TechPremiumCompany Announcements
Cynata Therapeutics Shares Clinical Progress
PremiumCompany Announcements
Cynata Therapeutics Lights Up International Cell Therapy Stage
PremiumCompany Announcements
Cynata Reports Breakthrough GvHD Treatment Results
PremiumCompany Announcements
Cynata Therapeutics Reports Options Expiry
PremiumCompany Announcements
Cynata Therapeutics Unveils Investor UpdateOptions Prices
Currently, No data available
---
Ownership Overview
3.72% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
96.28% Public Companies and
Individual Investors
CYYNF FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was $0.07 and its highest was $0.24 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Currently, no data Available
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 22, 2024 which is in 31 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 23, 2024. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 179,634,930 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in CYYNF
---
Cynata Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CYYNF Sentiment 92%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-85.62%
Trailing 12-Months
Asset Growth
-34.05%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which has branded Cymerus.
---
Technical Analysis
---